Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?
Case Based Panel Discussion - Advanced Non Squamous NSCLC, Low PD-L1 No Driver Mutation - Is There a Best Systemic Therapy Option?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Lung Cancer Video Library - Spanish Language: Video #6 What is maintenance therapy and why would it be recommended in advanced NSCLC?
For our 6th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss what is maintenance therapy and why it would be recommended in advanced NSCLC.
In this fourteenth video from the Targeted Therapies in Lung Cancer Patient Forum, we present the sixth from the afternoon breakout survivorship sessions, Love, Sex and Cancer, with Dr. Helen Coons.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
- 1 of 4
- View More
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".
Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.
Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
- 1 of 12
- View More
My wife is experiencing a second time brain tumor recurrence. She had her first occipital craniotomy back in 2011. On late Oct 2013 she began to...
My wife was on Tarceva for over 6 1/2 years. Then she developed acquired resistance to Tarceva with prevascular and supraclevical lymph nodes...